In pivotal studies canakinumab, a selective, human anti-IL-1β monoclonal antibody, demonstrated rapid control of disease activity and prevention of disease-related morbidities.8 9 However, long-term data of canakinumab in patients with CAPS are unavailable. The gene discussed is IL1B; the disease is cryopyrin-associated periodic syndrome.